Precision Chronotherapy (2026)

Medicine works on a clock. Receptor expression, drug absorption, hepatic metabolism, and target-organ sensitivity all cycle across the 24-hour day. Chronotherapy — aligning administration with those cycles — is not speculative fringe science. Decades of trials in cardiovascular, metabolic, respiratory, and psychiatric care show that time of day can change outcomes for the same approved dose.

Despite that evidence, the default clinical instruction remains population-average timing: once daily in the morning, with evening or bedtime dosing reserved for agents where a landmark trial forced the question. Individual chronotype, sleep timing, shift work, and seasonal light exposure are rarely captured before a dose schedule is fixed.

DIOS treats this as an infrastructure failure, not a patient behaviour failure. Until timing is measured, scored, and documented with the same seriousness as dose strength, avoidable variability will persist in every health system that prescribes at scale.

Guidelines encode what worked in trial populations — often morning dosing for operational simplicity. That design choice made sense when measurement was expensive. It makes less sense when passive circadian signal can be captured from a smartphone, refined with home sleep monitoring, and linked to formulary decisions.

The mismatch is structural: we personalise drug choice and increasingly dose strength, but we still hand the same clock instruction to a delayed sleep-phase patient, a night-shift worker, and a strict early-type retiree.

When timing is wrong, patients experience the failure as poor tolerability, weak effect, or unnecessary switches — not as a clock problem. That drives non-adherence, duplicated reviews, and therapeutic escalation that might have been avoided with a better-timed first regimen.

The clinical cost is not only suboptimal disease control. It is trust: patients who "fail" on paper-adherent timing may be labelled resistant or non-compliant when the schedule was never aligned to their biology.

In the NHS alone, poor medication timing contributes to over £300 million in wasted medicines annually — alongside reduced efficacy and avoidable hospital admissions. England’s national overprescribing review estimated that at least 10% of primary-care prescription items may not need to have been issued; a separate and larger story is medicines that are appropriate but taken at the wrong clock phase.

Medicines optimisation, cardiovascular prevention, metabolic risk, and medication safety all intersect with timing. Systems that ignore the when inherit repeat workload: switches, escalations, medicines reviews, and unused packs.

Chronotherapy evidence has rarely been operationalised because measurement, consent, governance, and workflow integration were missing. Clinicians cannot act on timing intelligence they do not receive in the record. Patients cannot follow guidance they are never given in personal, actionable form.

Point solutions — single-disease apps, static leaflets, or trial-specific bedtime rules — do not scale across formulary breadth. What is required is dose intelligence infrastructure: capture circadian signal, score confidence, produce schedule-ready output, and escalate to deeper diagnostics when risk is flagged.

DIOS begins with scan, score, and schedule — free at the point of use for patients and clinicians — then escalates through blood panels and FDA-cleared home sleep monitoring when indicated. The objective is not to replace prescriber judgement but to supply it with patient-specific timing evidence inside existing pathways.

Population dosing misses biology. Dose intelligence closes that gap — one patient, one clock, one schedule at a time.